⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.

Triple-Action Metabolic Compound
GLP-3 (RT)
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium Research Peptide.
From
$69.99From
$69.99Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Compound Information
Technical specifications
Stability Information
Sources & References
Peer-reviewed research
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
Jastreboff AM, et al.
GLP-3 (RT) for People with Type 2 Diabetes — A Phase 2 Trial
Rosenstock J, et al.
GLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease
Sanyal AJ, et al.
Effects of GLP-3 (RT) on Body Composition
Coskun T, et al.
Triple Agonism Based Therapies for Obesity
GLP-3 (RT) — A Game Changer in Obesity Pharmacotherapy
Efficacy and Safety of GLP-3 (RT) — Systematic Review & Meta-Analysis
TRIUMPH-4 Phase 3 Trial Results
Structural Analysis of Incretin Receptor Agonists
GLP-3 (RT) Compound Information
GLP-3 (RT) Clinical Trials Registry
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.



